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INTRODUCTION: Measuring Quality of Life (QoL)
has become a vital part of assessing lower limb ischemia
and peripheral vascular disease in international studies.
The 25-item VascuQoL was developed in UK English and
investigates 5 domains: symptoms, pain, activities, social
life and emotional state. Prior to use in an international
trial the measure underwent linguistic validation in 8 lan-
guages. METHODS: A QoL specialist coordinated the
translation process in each target country using the fol-
lowing methodology: 1) two forward translations by pro-
fessional, native speaking translators of the target lan-
guage fluent in English; 2) comparison and reconciliation
of the translations by a QoL specialist and translators; 3)
backward translation by a native English speaker; 4)
comparison of the source and backward versions; 5) re-
view of the translation by a clinician in each country; 6)
comprehension test in a sample target population; 7) in-
ternational harmonization. RESULTS: Linguistic and
conceptual issues emerged when translating idiomatic
phrases and response scales. Linguistic equivalents had to
be found for expressions such as “being (or becoming)
housebound” and “social activities”. The notions of
“discomfort”/“distress” did not have direct equivalents
in some languages where a single notion had to be used.
In most languages the frequency scale expressed in
amounts of time had to be simplified to establish equidis-
tant responses. CONCLUSIONS: A rigorous translation
methodology was performed to ensure conceptual equiv-
alence and acceptability of translations. International
feedback obtained through the translation process re-
vealed issues regarding the original instrument, indicating
that future amendments to the original may be necessary.
Future psychometric testing will be conducted to ensure
reliability and validity of each translation, appropriate-
ness of the questionnaire in each country and compara-
bility of data across countries.
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Physicians are increasingly challenged to maintain prac-
tice profits in the face of tightening reimbursements from
payers. While office visits generate a revenue stream for
physicians, it is not clear whether frequent lower com-
plexity visits (e.g., nurse visits to administer injections)
are actually profitable for physician practices. OBJEC-
TIVE: To develop an adaptable model and methodology
to evaluate profitability and financial incentives for vari-
ous in-office services provided by physicians and their
staff. METHODS: A literature and expert opinion based
model was developed from the physician practice per-
spective and was designed to be flexible for a variety of
office-based services. The practice cost component of the
model was developed using activity-based costing princi-
ples and included direct (drug acquisition, supplies, clini-
cal labor time, office visits) and indirect (malpractice in-
surance, office rent) expenses. The practice revenue
component of the model consisted of the reimbursement
amount from payers, including: drug reimbursement; of-
fice visits for physician evaluation, injections, end of
treatment follow-up and adverse events; and laboratory
tests. RESULTS: Practice profitability is inversely pro-
portional to the number of low complexity office visits
per year. Payer mix is also an important determinant of
profitability for in-office services, with Medicare reim-
bursements generally resulting in a net loss for practices
(5 loss per office visit for the lowest complexity ser-
vices) and typical managed care reimbursements provid-
ing only small profits (approximately 4 per low complex-
ity visit). CONCLUSIONS: Frequent low-complexity
office visits for administration of drug therapies do not
appear profitable for physician practices under Medicare
reimbursement. Alternative modes of drug delivery such
as implantable drug delivery devices or patient self-ad-
ministration may be more profitable for physician prac-
tices by allowing substitution of more highly reimbursed
office services.
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OBJECTIVE: To determine the non-workplace produc-
tivity costs (NWPC) for migraineurs using the human
capital approach (HCA) and replacement cost method
(RCM). METHOD: This was a supplemental analysis to
a prospective, observational migraine outcomes study
conducted at a managed care organization. Migraineurs
self-reported their work status, occupational category,
number of days missed from normal ‘activities’ outside of
paid job(s) due to migraine symptoms, number of days
performing normal ‘activities’ with migraine symptoms,
and percent effectiveness while performing normal ‘activ-
ities’ with migraine symptoms, at baseline, 3 months, and
6 months after the initiation of sumatriptan. Daily occu-
pational wages were obtained from the Bureau of Labor
Statistics. NWPC were calculated using the HCA and
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RCM as [(number of normal ‘activities’ days missed due
to migraine)  (number of normal ‘activities’ days per-
formed with migraine symptoms)(100%  % effective-
ness while working with symptoms)/100%]  (daily
wages). Daily wages for the corresponding occupational
category were used for patients with paid jobs. For pa-
tients without paid jobs, a daily wage of $0 and a daily
wage for private ‘household workers’ ($8) was assigned
for the HCA and RCM, respectively. RESULTS: There
were 178 patients who completed the study (90% female,
96% Caucasian, average age 39 years). There were 82%
of patients with paid jobs and 18% without paid jobs.
The 6 month NWPC lost were $184,143 and $203,505
using the HCA and RCM, respectively. CONCLUSION:
The RCM yields a higher estimate of NWPC of mi-
graineurs than the HCA. The HCA may underestimate
the NWPC of migraineurs. The method used to value
NWPC impacts the results of studies that are conducted
from the societal perspective.
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INTRODUCTION: The increase of patient-based assess-
ments in clinical trials has emphasized the need for cross-
culturally valid instruments to pool data across countries.
The Work Limitations Questionnaire (WLQ) consists of
25 questions divided into 4 scales, was developed in US
English and is designed for the assessment of the impact
of health problems on work. METHODS: Prior to use in
an international trial, the original questionnaire under-
went linguistic validation in 3 languages. Coordinated by
a QoL specialist in each target country, an internationally
recognised translation methodology was followed: pre-
liminary versions in Canadian French and US Spanish
were established after forward/backward translation.
The Canadian English version was established after a re-
view of the original by a QoL specialist in Canada.
Throughout the process the author clarified the concepts
underlying each item. RESULTS: Linguistic and concep-
tual issues arose during the translation process. The no-
tion of “work without stopping to take breaks or rests”
could not be translated literally, as in some countries, it is
illegal not to take breaks. It was therefore translated as
“work without stopping to take more breaks than
usual”. Likewise, the alternative use of “clients” and
“customers” in the original could be translated by only
one word in the translations. CONCLUSION: The steps
performed ensure the conceptual equivalence between the
original and the preliminary language versions. Testing
on a sample target population in each country and the
comparison of all languages will ensure the clarity, ap-
propriateness of wording and acceptability of the transla-
tions as well as their international harmonization. Psy-
chometric testing will be important to ensure similar
relationships among scales across countries.
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Simulation modeling can be used to obtain cost-effective-
ness information on drugs still in early development. OB-
JECTIVE: To construct a disease-based simulation model
characterizing the current patterns of treatment of os-
teoporosis and their associated clinical and economic
outcomes. The model can then be used to estimate the
marginal value of each proposed clinical characteristic of
a new drug for osteoporosis. METHODS: We performed
a systematic literature review of the epidemiology, treat-
ment guidelines and patterns of osteoporosis, as well as
of previous economic models and cost-effectiveness liter-
ature in this area. Interviews with clinicians and epidemi-
ologists were conducted to identify important parameters
for inclusion in the model. Information from these
sources was utilized to develop the model. RESULTS: A
state transition model has been constructed. Twenty-five
health states are used, with the inclusion of four fracture
sites (hip, wrist, vertebral and other), and other diseases
(i.e., breast cancer, coronary heart disease) that osteoporo-
sis interventions may impact. Simulation duration, co-
hort size, patient age matrices and distribution of initial
health states can all be varied, allowing a number of as-
sumptions to be tested. Quality adjusted life year values
and costs for the given year and subsequent years associ-
ated with each health state are included. The impact of
relative risks associated with each intervention are incor-
porated into the model, together with start and rise
times, fall and stop times. CONCLUSION: Through sim-
ulation modeling, data can be combined to estimate clini-
cal outcomes and economic consequences of osteoporosis
treatment early in the drug development process. Such in-
formation can then be used to establish the key clinical
characteristics that will need to be obtained in order to
achieve reimbursement.
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